PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 20260 citationsOpen Access

CL5D Hybrid Model Application to Cell Rejuvenation: A Phase-Dynamic Framework for Cancer and Neurodegeneration with Crystallographic Validation

View Full Paper
MCMrinmoy Chakraborty

Key Points

  • This research aims to apply the CL5D Hybrid Model to rejuvenate cells in cervical cancer and Alzheimer's disease contexts.
  • Developed the CL5D framework to model disease state transitions.
  • Utilized a three-component protocol: drug administration, mechanical shock, and energetic induction.
  • Applied BioGPS and Human Protein Atlas data to derive CL5D parameters.
  • Validated model parameters against crystallography structures.
  • BACE1 requires significantly less energy for transition than HeLa cells, with a 50.76 times difference in accessibility.
  • Established a cosmological scale factor for CL5D, corresponding approximately to atomic distances.
  • Identified a structural link between HeLa and BACE1 via shared gene clusters.

Abstract

We present the application of the CL5D Hybrid Model to a novel cell rejuvenation protocol targeting two distinct disease contexts: HeLa cervical cancer cells and BACE1-driven Alzheimer's neurodegeneration. The CL5D framework, a deterministic multi-phase mathematical architecture operating through four agents (At, Ab, Ex, T), models biological state transitions from a diseased N12 state to a high-energy pluripotent-analogous N2* state via a proposed three-component protocol: simultaneous drug administration, piezoelectric mechanical shock, and N2* energetic induction. The central mathematical mechanism is a 180-degree geometric inversion of the state-space decay vector (d to -d), converting an exponentially attenuating tunneling factor exp (-2kappad) into an amplifying factor exp (+2kappad). This term is used as a mathematical analogy for state transition in CL5D phase space, and does not imply literal quantum mechanical tunneling. Using BioGPS cell-line expression data for HeLa and Human Protein Atlas v25. 0 brain RNA data for BACE1, we derive disease-specific CL5D parameters and compute quantitative N2* generation thresholds. The required activation energy ECt is greater than or equal to 0. 003736 CL5D units for HeLa and 0. 0000736 CL5D units for BACE1, indicating that BACE1 is approximately 50. 76 times more energetically accessible to the protocol. We further validate the geometric inversion parameter against crystallographic structures from the Protein Data Bank: 6EJ2 (BACE1, 1. 46 Angstrom) and 2V5Z (MAOB, 1. 70 Angstrom), establishing a near-universal CL5D crystallographic scale factor of 1 CL5D unit approximately 1. 47 Angstrom. A shared Cluster 30 (White matter myelination, 1403 genes) connecting MAOB (HeLa Evolution set) and BACE1 provides a structural cross-link between the two disease domains. The extended domain coefficient phidomain = phigenetic x phiₚhysical x phiₑnvironmental is introduced to incorporate membrane viscosity and microenvironmental pH effects. This work positions CL5D as an empirically calibrated, biologically validated phase-dynamic complement to structural tools such as AlphaFold, which provides protein geometry but cannot predict phase transition thresholds or energetic accessibility.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mrinmoy Chakraborty (2026) studied this question.

synapsesocial.com/papers/69ba43584e9516ffd37a4800https://doi.org/10.5281/zenodo.19043350
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CL5D Phase IV Quantum Injection for Post-Mortem Cellular Reanimation: A Deterministic Mathematical Framework and In Silico Validation2026
  2. 2CL5D Phase-Dynamic Analysis of Neurodegenerative and Motor Neuron Disease Proteins: α-synuclein (Parkinson's) and Spastin (Hereditary Spastic Paraplegia) Beyond AlphaFold pLDDT2026
  3. 3CL5D Hybrid Model v3.0: Autonomous Computational Engine for Phase-Dynamic Systems2026
  4. 4CL5D Applied to Protein Oligomerization: Corrigendum to Paper 6 and Four Propositions Beyond AlphaFold pLDDT2026
  5. 5Restoration of the CL5D Scaling Symmetry in Malignant Systems: A Tri-Hybrid Intervention Protocol for TP53-Bypass and Phase IV Self-Rejuvenation.2026